The global hyaluronic acid-based dermal fillers market size was valued at USD 4.42 billion in 2022 and is expected to grow at a CAGR of 8.9% from 2023 to 2030. The primary factor driving the growth of the market are the growing demand for non-invasive aesthetic procedures and increasing awareness regarding the application of Hyaluronic Acid (HA) in beauty segment. In addition, increased investment in R&D for novel advanced innovations in dermal products is propelling the market's growth. The trend of aesthetic procedures is growing among men. More men are concerned regarding the negative impact of aging on their appearance & facial features; this is increasing the demand for facial dermal fillers. As per the ISPAS global survey, 12.2% population opting for non-surgical procedures involving HA based fillers, accounted for men.
The advent of technology is shaping the aesthetic market. In 2021, laser resurfacing treatment was introduced in the market having higher efficiency in addressing various skin concerns. The technology applies laser for solving all the dermal issues at once. In addition, the new technology is lower-invasive in response to the demand for non-invasive techniques. Key players are dedicated to the development of advanced solutions to have a competitive edge in the hyaluronic acid market. The increasing number of new product approvals is propelling market opportunities. For instance, in January 2022, RHA Redensity, a novel dermal filler for reducing the wrinkles on skin, received U.S. FDA approval RHA Redensity is a gel implant produced from sodium hyaluronic acid which is injected into particular locations of the facial tissue for smoothening out lines & wrinkles.
The initial phase of the pandemic negatively impacted the market. The governments & healthcare players had increased focus for supporting the diagnostics & treatment methods for COVID-19. The disruption in supply of products & equipment for aesthetic procedures & restrictions on the procedures drastically impacted the market. The later part of 2020 witnessed increasing demand for the market. According to the data by the International Society of Plastic Surgery (ISAP in 2020, the overall demand for nonsurgical procedures, hair removal treatment and primarily fillers increased. The demand is expected to be higher post COVID-19 due to rising importance of aesthetic appearance & growing preference for non-invasive procedure.
The stringent government guidelines & regulations in the U.S., Europe Union & international markets for the development, branding & production of HA-based products are restraining the market. These stringent laws enable that quality products are utilized by healthcare facilities, including doctors as well as other end users. For instance, according to an 2018 FDA report, Juvederm must only be available for sale as well as injected with a licensed healthcare provider's recommendation. The FDA has also recommended patients and their doctors to refrain from using Juvederm Ultra 2, 3, & 4 due to non-approval of the product by U.S. FDA. This is restricting the accessibility of latest products.
Based on the product, the market is segmented into single-phase & duplex products. The single-phase segment had the highest market shares in 2022 of 54.2% and is estimated to have the highest demand during the forecasted period. The segmented is estimated to grow rapidly owing to its variety of applications in skin & facial procedures, lower side effects & advancement of technology resulting in the development of novel fillers.
Dermatologists are preferring single-phase products for the repair of soft tissue facial issues as the uncross-linked hyaluronic acid boosts production of collagen & elastin providing the skin a younger and healthy glow. Single-phase products don't go through the sizing technique, breaking down the gel, during the production process. Hylacross technology is applied to the production of single-phase fillers like Juvederm Ultra, resulting in product durability with potential benefits.
Cohesive intensified matrix technique is applied to make duplex hyaluronic acid products. The enhanced durability, duplex products is resulting in them being employed for treating glabellar lines & nasolabial folds. According to a study on Belotero HA filler, CPM technological solutions have soft flowing characteristics allowing for smooth injection as well as integration of homogeneous tissue integration.
Wrinkle correction dominated the market in 2022 with a share of 28.7%and is estimated to have a significant growth during the forecast period. Based on application the market is segmented into wrinkle correction, lip augmentation, rhinoplasty and others. This is due to growing customer awareness & desire for youthful appearance, technological advancements in hyaluronic acid-based treatment and growing number of new products and procedures for antiwrinkle treatment.
Lip augmentation is expected to have lucrative growth during the forecast period owing to increasing contributions from key market players. Lip augmentation is a cosmetic procedure performed for enhancing the volume of lips through enlargement by application of fillers that may be temporary or permanent. Hyaluronic Acid-based Dermal Fillers are widely applied injections for plumping and defining lips. Hyaluronic acid facilitates a thickening appearance of lips by attaching to the water molecules present inside the skin. Increasing awareness, growth in disposable income, change in lifestyle & surging demand for filler are expected to further propel the growth.
Dermal Fillers based involving hyaluronic acid are applied in revision rhinoplasty for smoothing irregularities/asymmetries of nose. The procedure is considered as the most complicated procedure in plastic procedures. This procedure is mandatory for 5- 12% of rhinoplasty patients. It is also gaining popularity among the population desiring to change their nasal appearance. Rising awareness of aesthetic procedures, launch of advanced treatment procedures like 3D computer-assisted technologies is propelling the demand for rhinoplasty market.
The North America region held the largest market share of 46.4% in 2022 due to the increased number of non-invasive cosmetic procedures performed, growing investment on research & infrastructure. Furthermore, the presence of key market leaders in the region is driving market opportunities in the region.
Europe is expected to have significant growth during the forecast period. This can be attributed to the rising aging population and increasing preference for anti-aging procedures involving Hyaluronic Acid-based Dermal Fillers. Germany is one of the leading countries in Europe in terms of number of hyaluronic acid-based dermal filler procedures. As per the International Society of Plastic Surgery, 236,778 surgeries were carried out in Germany in 2020.
Over the forecast period, the Asia Pacific region is expected to have the fastest growth. The market's expansion is attributed to several factors such as strategic activities by key market players for dermal fillers, rising awareness of non-invasive techniques for aesthetic treatment in the region and an increase in men opting for injectable fillers for jawline & chin augmentation. However, the higher cost of surgeries is restraining market growth.
The market is fragmented and highly competitive. To key market players are focusing on regional expansion & new product development. For Instance, A.Menarini plans to introduce a line of HA-based fillers with Lidocaine in October 2021. The line of products would be produced using Menarini's proprietary or exclusive XTR new tech, enabling fillers having distinct rheological characteristics for supporting variety of clinical indications for rejuvenation & facial volume restoration. Some of the prominent market players in the hyaluronic market include-
Allergan; Galderma Laboratories
L.P.; Merz Pharmaceuticals
Genzyme Corporation
Anika Therapeutics Inc.
LG Life Sciences,
LTD (LG Chem)
Bio plus Co. Ltd.
Sculpt Luxury
Dermal Fillers Ltd;
Bioxis Pharmaceutical;
Sinclair Pharma; Laboratories
Vivacy; Bohus Biotech AB
Report Attribute |
Details |
Market size value in 2023 |
USD 4.74 billion |
Revenue forecast in 2030 |
USD 8.59 billion |
Growth rate |
CAGR of 8.9% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, application, region |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait; Rest of Europe; Rest of Latin America; Rest of Asia Pacific; Rest of MEA |
Key companies profiled |
AbbVie; Galderma Laboratories, L.P.; Merz Pharmaceuticals , Genzyme Corporation, Anika Therapeutics Inc., LG Life Sciences, LTD (LG Chem), Bio plus Co. Ltd., Sculpt Luxury, Dermal Fillers Ltd;, Bioxis Pharmaceutical; Sinclair Pharma; Laboratories, Vivacy; Bohus Biotech AB |
Customization scope |
Free report customization (equivalent up to 8 analyst working days) with purchase. Addition or alteration to country & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the hyaluronic acid-based dermal fillers market report on the basis of product, application, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Single Phase Products
Duplex Products
Application Outlook (Revenue, USD Million, 2018 - 2030)
Wrinkle Correction
Lip Augmentation
Rhinoplasty
Others
Region Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
China
Japan
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global hyaluronic acid-based dermal fillers market size was estimated at USD 4.42 billion in 2022 and is expected to reach USD 4.74 billion in 2023..
b. The global hyaluronic acid-based dermal fillers market is expected to grow at a compound annual growth rate of 8.9% from 2023 to 2030 to reach USD 8.59 billion by 2030.
b. The wrinkle removal segment dominated the hyaluronic acid-based dermal fillers market with a share of around 28.6% in 2022. This can be attributed to the increasing trend of social networking websites, insistent peer pressure, and popularity of the procedure among women as well as men of all age groups.
b. Some key players operating in the hyaluronic acid-based dermal fillers market include Allergan; Galderma Laboratories L.P.; Merz Pharmaceuticals; Genzyme Corporation; Anika Therapeutics Inc.; LG Life Sciences, LTD (LG Chem); Bioplus Co. Ltd.; Sculpt Luxury Dermal Fillers Ltd; Bioxis Pharmaceutical; Sinclair Pharma; Laboratories Vivacy; and Bohus Biotech AB.
b. Key factors that are driving the hyaluronic acid-based dermal fillers market growth include increasing demand for youthful and flawless skin via noninvasive and outpatient aesthetic dermatology techniques and a rise in medical tourism for aesthetic procedures.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.